Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Teva Pharmaceutical Industries Ltd.’s $40.5 billion acquisition of Allergan plc’s generic pharmaceutical business would be anticompetitive.
Brief of the United States Department of Justice and the Federal Trade Commission as amici curiae, urging the Fifth Circuit to dismiss the appeal for lack of jurisdiction or, if the Court finds jurisdiction, to reject application of the state action doctrine to this case because the...
On September 9, 2016, the Federal Trade Commission and Department of Justice filed a joint amicus brief urging the U.S. Court of Appeals for the Fifth Circuit to dismiss an appeal by the Texas Medical Board of a district court decision holding that Board regulations restricting telehealth services...
Just include pdfs of the copy signature pages on the DVD, then submit the original signatures within two business days of filing.
The letters, certification and affidavit should be searchable PDFs.
In addition to applying the filename naming conventions, the first...
Yes. The change is intended to reach acquiring persons, such as funds and holding companies, where the financials of the UPE do not necessarily show or break out information about the operating company that contributes to the overlap. We are not interested in the...
Informal 0307004 is superseded by PNPM 152. “Sales in or into” are the same for both 802.50 and 802.51.
From: [REDACTED]Sent: Friday, September 2, 2016 4:25 PMTo: firstname.lastname@example.org; 'Whitehead, Nora' <email@example.com>Subject: Ocean Shipping Sales "in or...
We agree that the creation and transfer of shares to Trusts B, C and D would be exempt under 802.71.
From: [REDACTED]Sent: Wednesday, August 31, 2016 3:55 PMTo: Walsh, Kathryn E.; Storm, EvanSubject: 802.71 Question
Hi Kate, Evan -
I hope you’re doing well. I...
The acquirer will have to do a FMV under 801.10(c)(3), which the board can delegate to another.
From: [REDACTED]Sent: Thursday, August 25, 2016 4:25 PMTo: Gillis, Diana L.Subject: Question Regarding Determination of Value of Assets
Correct, the 4c/d documents are limited to the backside transaction. Of course, any such documents that also mention the main transaction are still responsive in full.
From: [REDACTED]Sent: Friday, August 26, 2016 11:01 AMTo: Gillis, Diana L.Subject: Query re: Item 4(c) / 4(d)
We still require physical signatures and do not accept e-signatures.
Premerger Notification Office
Federal Trade Commission
202-326-3434 | firstname.lastname@example.org
We view C as an entity, the others are foreign agencies.
From: [REDACTED]Sent: Monday, August 22, 2016 1:21 PMTo: Walsh, Kathryn E.; Berg, Karen E.; Gillis, Diana L.Cc: [REDACTED]Subject: Question on Foreign Vehicles as "Entities"
Dear Kate, Karen and Diana.
We would view this as a formation; A and B are not disappearing as a result, nor are they becoming subsidiaries of a new parent entity. See Interpretation 211 in the PNPM for discussion of consolidations.
From: [REDACTED]Sent: Monday, August 22, 2016 2:05 PMTo:...
That is correct.
From: [REDACTED]Sent: Wednesday, August 17, 2016 11:59 AMTo: Storm, Evan; Gillis, Diana L.Subject: Quick Question re: 4b
Evan and Diana,
Hi [REDACTED], thanks for writing this out. My responses are below in red.
From: [REDACTED]Sent: Tuesday, August 09, 2016 9:53 AMTo: Berg, Karen E.Subject: Item 6b
Thanks for talking to me earlier this morning. As I mentioned my question is on Item 6b.
From: Storm, EvanSent: Thursday, August 04, 2016 12:23 PMTo: [REDACTED]Subject: RE: Determining sales in or into the US under 802.50 and 802.51
As long as the products aren’t designed specifically for the US, to the exclusion of other markets, these would not be US sales....
In this particular case, we agree that your S.C.A. should be treated as a non-corporate entity. Thanks for laying out your case so thoroughly.
From: [REDACTED]Sent: Thursday, July 21, 2016 12:48 PMTo: Walsh, Kathryn E.; Whitehead, Nora; Berg, Karen E.;...